Synthesis and Anti-HIV-1 Evaluation of Some Novel MC-1220 Analogs as Non-Nucleoside Reverse Transcriptase Inhibitors
作者:Yasser M. Loksha、Erik B. Pedersen、Roberta Loddo、Paolo La Colla
DOI:10.1002/ardp.201600008
日期:2016.5
salt of 2,6‐difluorophenylacetonitrile followed by treatment with aqueous sodium hydroxide in methanol, alkylation, reduction, halogenation, and/or acidic hydrolysis. All synthesized compounds were evaluated for their activity against HIV‐1. The most active compound in this study was compound 7, which showed activity against HIV‐1 comparable to that of MC‐1220. The only difference in structure between
Facile synthesis of the NNRTI microbicide MC-1220 and synthesis of its phosphoramidate prodrugs
作者:Yasser M. Loksha、Erik B. Pedersen、Paolo La Colla、Roberta Loddo
DOI:10.1039/c5ob02055g
日期:——
A facile and novelsyntheticroute to MC-1220 was achieved by condensation of 4,6-dichloro-N,N-5-trimethylpyrimidin-2-amine (1) with the sodium salt of 2,6-difluorophenylacetonitrile, followed by methylation and strong acidic hydrolysis. The prodrugs of MC-1220 were synthesized by reaction of chlorophosphoramidate derivatives (7a–e) or α-acetobromoglucose with the sodium salt of MC-1220. The stability
Synthesis and anti-HIV-1 evaluation of 1,5-disubstituted pyrimidine-2,4-diones
作者:Yasser M. Loksha、Daniel Globisch、Erik B. Pedersen、Paolo La Colla、Gabriella Collu、Roberta Loddo
DOI:10.1002/jhet.5570450434
日期:2008.7
1,5-Disubstitutedpyrimidine-2,4-diones were synthesized by fusion of 5-bromouracil with an aniline derivative followed by coupling with benzyl halide whereas the opposite synthesis sequence failed. Also 4,6-dichloro-N,N,5-trimethylpyrimidin-2-amine was treated with phenols. The products were tested for their activity against HIV-1.
A Novel Synthetic Route for the Anti-HIV Drug MC-1220 and its Analogues
作者:Yasser M. Loksha、Daniel Globisch、Roberta Loddo、Gabriella Collu、Paolo La Colla、Erik B. Pedersen
DOI:10.1002/cmdc.201000244
日期:2010.11.8
Easy street: Herein we describe a novel and practical synthesis of the anti‐HIV compound MC‐1220. Through the use of inexpensive reagents and commercially available starting materials, MC‐1220 and itsanalogues are more easily accessed by a four‐step procedure involving a key reduction step.